A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
Primary Purpose
Non-Eosinophilic Asthma
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
AVTX-002
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Non-Eosinophilic Asthma focused on measuring Non-Eosinophilic Asthma, AVTX-002
Eligibility Criteria
Inclusion Criteria:
- Documented non-eosinophilic asthma diagnosis (<300 eosinophils/μL).
- Symptoms consistent with a diagnosis of asthma that is poorly controlled as determined by an ACQ score ≥ 1.5.
- Poorly controlled asthma despite the use of a Long-Acting Beta-Agonists and Inhaled Corticosteroid for at least 3 consecutive months immediately prior to screening.
- Subjects must have had at least one asthma exacerbation in the last 24 months.
Exclusion Criteria:
- Pulmonary disease other than asthma.
- Currently on biologic therapy. Previous biologic therapy is permitted with adequate washout (12 weeks or 5 half-lives, whichever is longer).
- Use of systemic immunosuppressants within the last 6 months.
- Use of systemic corticosteroids within 6 weeks prior to Screening or use of antibiotics within 4 weeks prior to Screening.
- Subject has alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) >5 upper limit of normal (ULN) and/or serum creatinine concentration >1.5 mg/dL.
- Subject has hemoglobin ≤10 g/dL, neutrophils ≤1,500/μl, and/or platelets ≤75,000/μl.
Sites / Locations
- Tucson Neuroscience Research - M3, Wake Research
- Center For Clinical Trials of Sacramento
- Allergy and Asthma Medical Group of the Bay Area
- Center For Clinical Trials of San Gabriel
- IMMUNOe Research Centers
- National Jewish Health
- Helix Biomedics, LLC
- Pro-Care Research Center, Corp.
- Suncoast Research Group LLC
- Suncoast Research Associates LLC
- Innovation Medical Research Center
- ASHA Clinical Research-Munster, LLC
- Family Allergy and Asthma Research Institute
- Continental Clinical Solutions, LLC
- Pulmonary Research Institute of Southeast Michigan
- Midwest Clinical Research
- Meridian Clinical Research
- OK Clinical Research
- Affinity Health
- Amarillo Center For Clinical Research
- South Texas Medical Research Institute, Inc
- Pioneer Research Solutions
- Meridian Clinical Research
- Clinical Research Partners, LLC
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
AVTX-002
Placebo
Arm Description
Approximately 40 subjects will receive AVTX-002 at a dose of 600 mg three times during the study.
Approximately 40 subjects will receive placebo sourced as normal saline three times during the study.
Outcomes
Primary Outcome Measures
To assess the ability of AVTX-002 to improve asthma control in subjects with poorly controlled non-eosinophilic asthma (NEA) based on the proportion of patients who experience asthma related events.
Proportion of patients who experience any of the following asthma related events:
≥6 additional reliever puffs of Short-Acting Beta-Agonist (compared to baseline) in a 24-hour period on 2 consecutive days or,
increase in inhaled corticosteroid dose ≥4 times than the dose at baseline or,
a decrease in peak flow of 30% or more (compared to baseline) on 2 consecutive days of treatment, or
an asthma exacerbation requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days, or
a hospitalization or emergency room visit because of an asthma exacerbation
Secondary Outcome Measures
To assess the safety and tolerability of AVTX-002.
Change from baseline in forced expiratory volume in 1 second (FEV1)
To assess the safety and tolerability of AVTX-002.
Time to asthma exacerbation
To assess the safety and tolerability of AVTX-002.
Change from baseline in fractional exhaled nitric oxide (FeNO)
To assess the safety and tolerability of AVTX-002.
Change from baseline in Asthma Control Questionnaire (ACQ)
To assess the safety and tolerability of AVTX-002.
Change from baseline in Standardized Asthma Quality of Life Questionnaire for 12 years and older (AQLQ(S)+12)
To assess the safety and tolerability of AVTX-002.
Change from baseline in Asthma Symptom Diary Score
To assess the safety and tolerability of AVTX-002.
Change from baseline in European Quality of Life - 5 Dimension 5 level Questionnaire
To assess the safety and tolerability of AVTX-002.
Change from baseline in Patient Global Impression of Change/Severity
To assess the safety and tolerability of AVTX-002.
Change from baseline in Clinician Global Impression of Improvement/Severity
To assess the safety and tolerability of AVTX-002.
Incidence of short-acting beta agonist (SABA) use
To assess the safety and tolerability of AVTX-002.
Safety and tolerability will be assessed by incidence of adverse events (AEs). Clinically significant changes from baseline in clinical laboratory tests, vital signs, and physical examinations will be recorded as AEs.
To evaluate biomarkers of pharmacodynamic (PD) activity and mechanism of action of AVTX-002.
Change from baseline in serum soluble LIGHT levels
To evaluate the immunogenicity of AVTX-002.
Incidence of anti-drug antibodies (ADAs)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05288504
Brief Title
A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
Official Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
February 24, 2022 (Actual)
Primary Completion Date
May 11, 2023 (Actual)
Study Completion Date
May 11, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Avalo Therapeutics, Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective of this study is to evaluate the efficacy of AVTX-002 compared with placebo in patients with poorly controlled non-eosinophilic asthma (NEA).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Eosinophilic Asthma
Keywords
Non-Eosinophilic Asthma, AVTX-002
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
91 (Actual)
8. Arms, Groups, and Interventions
Arm Title
AVTX-002
Arm Type
Experimental
Arm Description
Approximately 40 subjects will receive AVTX-002 at a dose of 600 mg three times during the study.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Approximately 40 subjects will receive placebo sourced as normal saline three times during the study.
Intervention Type
Drug
Intervention Name(s)
AVTX-002
Other Intervention Name(s)
CERC-002, AEVI-002, MDGN-002
Intervention Description
Dose of 600 mg administered subcutaneously three times during the study.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo sourced as normal saline administered subcutaneously three times during the study.
Primary Outcome Measure Information:
Title
To assess the ability of AVTX-002 to improve asthma control in subjects with poorly controlled non-eosinophilic asthma (NEA) based on the proportion of patients who experience asthma related events.
Description
Proportion of patients who experience any of the following asthma related events:
≥6 additional reliever puffs of Short-Acting Beta-Agonist (compared to baseline) in a 24-hour period on 2 consecutive days or,
increase in inhaled corticosteroid dose ≥4 times than the dose at baseline or,
a decrease in peak flow of 30% or more (compared to baseline) on 2 consecutive days of treatment, or
an asthma exacerbation requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days, or
a hospitalization or emergency room visit because of an asthma exacerbation
Time Frame
Through Week 14
Secondary Outcome Measure Information:
Title
To assess the safety and tolerability of AVTX-002.
Description
Change from baseline in forced expiratory volume in 1 second (FEV1)
Time Frame
Through Week 14
Title
To assess the safety and tolerability of AVTX-002.
Description
Time to asthma exacerbation
Time Frame
Through Week 14
Title
To assess the safety and tolerability of AVTX-002.
Description
Change from baseline in fractional exhaled nitric oxide (FeNO)
Time Frame
Through Week 14
Title
To assess the safety and tolerability of AVTX-002.
Description
Change from baseline in Asthma Control Questionnaire (ACQ)
Time Frame
Through Week 14
Title
To assess the safety and tolerability of AVTX-002.
Description
Change from baseline in Standardized Asthma Quality of Life Questionnaire for 12 years and older (AQLQ(S)+12)
Time Frame
Through Week 14
Title
To assess the safety and tolerability of AVTX-002.
Description
Change from baseline in Asthma Symptom Diary Score
Time Frame
Through Week 14
Title
To assess the safety and tolerability of AVTX-002.
Description
Change from baseline in European Quality of Life - 5 Dimension 5 level Questionnaire
Time Frame
Through Week 14
Title
To assess the safety and tolerability of AVTX-002.
Description
Change from baseline in Patient Global Impression of Change/Severity
Time Frame
Through Week 14
Title
To assess the safety and tolerability of AVTX-002.
Description
Change from baseline in Clinician Global Impression of Improvement/Severity
Time Frame
Through Week 14
Title
To assess the safety and tolerability of AVTX-002.
Description
Incidence of short-acting beta agonist (SABA) use
Time Frame
Through Week 14
Title
To assess the safety and tolerability of AVTX-002.
Description
Safety and tolerability will be assessed by incidence of adverse events (AEs). Clinically significant changes from baseline in clinical laboratory tests, vital signs, and physical examinations will be recorded as AEs.
Time Frame
Through Week 14
Title
To evaluate biomarkers of pharmacodynamic (PD) activity and mechanism of action of AVTX-002.
Description
Change from baseline in serum soluble LIGHT levels
Time Frame
Through Week 14
Title
To evaluate the immunogenicity of AVTX-002.
Description
Incidence of anti-drug antibodies (ADAs)
Time Frame
Through Week 14
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Documented non-eosinophilic asthma diagnosis (<300 eosinophils/μL).
Symptoms consistent with a diagnosis of asthma that is poorly controlled as determined by an ACQ score ≥ 1.5.
Poorly controlled asthma despite the use of a Long-Acting Beta-Agonists and Inhaled Corticosteroid for at least 3 consecutive months immediately prior to screening.
Subjects must have had at least one asthma exacerbation in the last 24 months.
Exclusion Criteria:
Pulmonary disease other than asthma.
Currently on biologic therapy. Previous biologic therapy is permitted with adequate washout (12 weeks or 5 half-lives, whichever is longer).
Use of systemic immunosuppressants within the last 6 months.
Use of systemic corticosteroids within 6 weeks prior to Screening or use of antibiotics within 4 weeks prior to Screening.
Subject has alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) >5 upper limit of normal (ULN) and/or serum creatinine concentration >1.5 mg/dL.
Subject has hemoglobin ≤10 g/dL, neutrophils ≤1,500/μl, and/or platelets ≤75,000/μl.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Garry Neil, MD
Organizational Affiliation
Avalo Therapeutics, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Tucson Neuroscience Research - M3, Wake Research
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85710
Country
United States
Facility Name
Center For Clinical Trials of Sacramento
City
Sacramento
State/Province
California
ZIP/Postal Code
95823
Country
United States
Facility Name
Allergy and Asthma Medical Group of the Bay Area
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94598
Country
United States
Facility Name
Center For Clinical Trials of San Gabriel
City
West Covina
State/Province
California
ZIP/Postal Code
91790-3402
Country
United States
Facility Name
IMMUNOe Research Centers
City
Centennial
State/Province
Colorado
ZIP/Postal Code
80112
Country
United States
Facility Name
National Jewish Health
City
Denver
State/Province
Colorado
ZIP/Postal Code
80206
Country
United States
Facility Name
Helix Biomedics, LLC
City
Boynton Beach
State/Province
Florida
ZIP/Postal Code
33435
Country
United States
Facility Name
Pro-Care Research Center, Corp.
City
Miami Gardens
State/Province
Florida
ZIP/Postal Code
33014
Country
United States
Facility Name
Suncoast Research Group LLC
City
Miami
State/Province
Florida
ZIP/Postal Code
33135
Country
United States
Facility Name
Suncoast Research Associates LLC
City
Miami
State/Province
Florida
ZIP/Postal Code
33137
Country
United States
Facility Name
Innovation Medical Research Center
City
Palmetto Bay
State/Province
Florida
ZIP/Postal Code
33157
Country
United States
Facility Name
ASHA Clinical Research-Munster, LLC
City
Hammond
State/Province
Indiana
ZIP/Postal Code
46324
Country
United States
Facility Name
Family Allergy and Asthma Research Institute
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40215
Country
United States
Facility Name
Continental Clinical Solutions, LLC
City
Towson
State/Province
Maryland
ZIP/Postal Code
21212
Country
United States
Facility Name
Pulmonary Research Institute of Southeast Michigan
City
Farmington Hills
State/Province
Michigan
ZIP/Postal Code
48336
Country
United States
Facility Name
Midwest Clinical Research
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States
Facility Name
Meridian Clinical Research
City
Lincoln
State/Province
Nebraska
ZIP/Postal Code
68510
Country
United States
Facility Name
OK Clinical Research
City
Edmond
State/Province
Oklahoma
ZIP/Postal Code
73034
Country
United States
Facility Name
Affinity Health
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
Amarillo Center For Clinical Research
City
Amarillo
State/Province
Texas
ZIP/Postal Code
79124
Country
United States
Facility Name
South Texas Medical Research Institute, Inc
City
Boerne
State/Province
Texas
ZIP/Postal Code
78006
Country
United States
Facility Name
Pioneer Research Solutions
City
Houston
State/Province
Texas
ZIP/Postal Code
77099
Country
United States
Facility Name
Meridian Clinical Research
City
Portsmouth
State/Province
Virginia
ZIP/Postal Code
23703
Country
United States
Facility Name
Clinical Research Partners, LLC
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23226
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
We'll reach out to this number within 24 hrs